The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Future lung cancer drug approvals in the UK
Alastair Greystoke, PhD, MBChB, PhD, MRCP, University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, provides an overview of anticipated lung cancer drug approvals for non-small-cell lung cancer (NSCLC), including the KRAS inhibitor sotorasib, tepotinib and capmatinib, which both are MET inhibitors, as well as amivantamab and osimertinib. Dr Greystoke additionally discusses the prevalence of various mutations across different age groups, with ALK, RET, ROS1, and EGFR exon 20 insertion mutations being more common in younger patients and MET mutations being more frequent in older patients. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Disclosures
Prof. Greystoke reports consultancy and speaker fees from AstraZeneca, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Janssen/ J and J, MSD, Novartis, Pfizer, Lilly, Takeda and Roche; and research funding from AstraZeneca. He is also the clinical Lead for Cancer North East England Hull and Yorkshire Genomic Laboratory Hub and a member of the National Test Directory Evaluation Working Group.
